https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36396 Wed 28 Feb 2024 14:54:48 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41947 Wed 22 Mar 2023 14:31:19 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:9164 Wed 11 Apr 2018 11:29:56 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31072 v standard], 0.96; 90% CI, 0.77 to 1.2). Ten deaths as a result of prostate cancer occurred in the short arm and 12 in the standard arm. No significant differences were detected between arms for grade ≥ 3 late genitourinary and GI toxicity. Conclusion: The hypofractionated RT regimen used in this trial was not inferior to conventional RT and was not associated with increased late toxicity. Hypofractionated RT is more convenient for patients and should be considered for intermediate-risk prostate cancer.]]> Wed 02 Mar 2022 14:26:55 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12469 Sat 24 Mar 2018 08:16:30 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:12323 Sat 24 Mar 2018 08:11:36 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26274 Sat 24 Mar 2018 07:40:16 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:47485 Mon 23 Jan 2023 11:48:41 AEDT ]]>